JP2023531675A5 - - Google Patents
Info
- Publication number
- JP2023531675A5 JP2023531675A5 JP2022578935A JP2022578935A JP2023531675A5 JP 2023531675 A5 JP2023531675 A5 JP 2023531675A5 JP 2022578935 A JP2022578935 A JP 2022578935A JP 2022578935 A JP2022578935 A JP 2022578935A JP 2023531675 A5 JP2023531675 A5 JP 2023531675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- berzutifan
- hif
- inhibitor
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042307P | 2020-06-22 | 2020-06-22 | |
| US63/042,307 | 2020-06-22 | ||
| US202163146915P | 2021-02-08 | 2021-02-08 | |
| US63/146,915 | 2021-02-08 | ||
| PCT/US2021/038172 WO2021262563A1 (en) | 2020-06-22 | 2021-06-21 | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531675A JP2023531675A (ja) | 2023-07-25 |
| JP2023531675A5 true JP2023531675A5 (cg-RX-API-DMAC7.html) | 2024-06-27 |
| JP7750884B2 JP7750884B2 (ja) | 2025-10-07 |
Family
ID=79281740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578935A Active JP7750884B2 (ja) | 2020-06-22 | 2021-06-21 | HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210838A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4168008B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7750884B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230026493A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115803629A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021296151A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026094A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183852A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3072250T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022016406A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021262563A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
| US20240327929A1 (en) * | 2021-08-12 | 2024-10-03 | Merck Sharp & Dohme Llc | Dosage regimen for administration of belzutifan |
| EP4425678A1 (en) | 2023-02-28 | 2024-09-04 | LG Energy Solution, Ltd. | Separator for electrochemical device and electrochemical device comprising same |
| JPWO2024204679A1 (cg-RX-API-DMAC7.html) * | 2023-03-31 | 2024-10-03 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| EP3866927A4 (en) * | 2018-10-17 | 2022-07-27 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
-
2021
- 2021-06-21 JP JP2022578935A patent/JP7750884B2/ja active Active
- 2021-06-21 CN CN202180049537.5A patent/CN115803629A/zh active Pending
- 2021-06-21 KR KR1020237002565A patent/KR20230026493A/ko active Pending
- 2021-06-21 MX MX2022016406A patent/MX2022016406A/es unknown
- 2021-06-21 ES ES21828761T patent/ES3072250T3/es active Active
- 2021-06-21 US US18/009,115 patent/US20230210838A1/en active Pending
- 2021-06-21 EP EP21828761.3A patent/EP4168008B1/en active Active
- 2021-06-21 BR BR112022026094A patent/BR112022026094A2/pt unknown
- 2021-06-21 EP EP26162704.6A patent/EP4775271A2/en active Pending
- 2021-06-21 CA CA3183852A patent/CA3183852A1/en active Pending
- 2021-06-21 WO PCT/US2021/038172 patent/WO2021262563A1/en not_active Ceased
- 2021-06-21 AU AU2021296151A patent/AU2021296151A1/en active Pending
-
2022
- 2022-12-16 MX MX2025014865A patent/MX2025014865A/es unknown